| Description |
Neurodegenerative diseases such as Alzheimer's and Parkinson's disease and conditions such as stroke disrupt the quality of life for patients, extracts an enormous emotional and physical strain on caregivers, and cost society billions of dollars annually. Increasing numbers of elderly people in the population has resulted in a sharp increase in the prevalence of these neurological conditions. Underlying a majority of these disorders is the abnormal degeneration of neurons. In most instances, the etiological causes are unknown and they have a progressive development. While symptomatic treatments are available for many neurodegenerative disorders, drugs to reduce or prevent the neuronal loss in patients have yet to be identified. Intense research over the past few years has generated a rich and complex body of information about the mechanisms and pathophysiology of neurodegenerative conditions. This knowledge has provided the opportunity to find novel targets for drug development and resulting in the initiation of several promising clinical trials.
The conference focuses on the latest and most exciting research findings in the identification of novel molecular targets and the development of potential therapeutic strategies for neurodegenerative conditions. We have an excellent list of speakers from academia, industry and government whose presentations will cover a range of topics within the area of neurodegeneration and therapy and with information from cell culture models to clinical trials.
The conference will take place in Boston on Monday, October 10 and Tuesday, October 11. Please bring this conference to the attention of your colleagues, post-doctoral fellows and students who may benefit from attending the meeting. Please register early and submit an abstract. Come to Boston earlier or stay later and enjoy the many historic and cultural delights of this beautiful city.
It will be my pleasure to welcome you to the first annual conference on Therapeutic Strategies against Neurodegenerative Conditions in Boston.
Sincerely,
Santosh R. D'Mello, Ph.D.
Conference Chairperson
|
|
| Additional Information |
AGENDA
<table border="0" width="650" cellspacing="0" cellpadding="0">
<td colspan="2" width="650">
<p class="MsoNormal" align="left">
<span style="font-family: Arial; background: silver"><font size="3">DAY
1 - Monday, October 10, 2005</font></span>
|
<td colspan="2">
|
<td width="49"><font face="Arial" size="2" color="#0000FF">7:15</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">Registration
and Breakfast </font>
|
<td width="49">
<td width="552">
|
<td width="49"><font face="Arial" size="2" color="#0000FF">8:15</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">Opening
Remarks</font>
|
<td width="49">
<td width="552">
|
<td width="49"><font face="Arial" size="2" color="#0000FF">8:30</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">
Neuroprotective Approaches to Alzheimer's Disease</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">John
Davis, </font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">
GlaxoSmithKline</font>
|
<td width="49">
<td width="552">
|
<td width="49"><font size="2" face="Arial" color="#0000FF">9:00</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">Amyloid-based
Therapeutic Strategies for Alzheimer's Disease</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">Rusell
Rydel, Ph.D., Vice President, Pharmacology </font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">Elan
Pharmaceuticals</font>
|
<td width="49">
<td width="552">
|
<td width="49"><font size="2" face="Arial" color="#0000FF">9:30</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">Drug
Development Targets and Strategies for Neuroprotection and
Neurorestoration in Alzheimer's Disease</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">Martin
Tolar, M.D., Ph.D, Director, Clinical Strategic Partnerships</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">Pfizer
Global Research</font>
|
<td width="49">
<td width="552">
|
<td width="49"><font face="Arial" size="2" color="#0000FF">10:00</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">APOE4 and
Alzheimer's Disease: From Susceptibility Gene Variant to Clinical Trial
to New Drug Discovery</font>
|
<td width="49" height="22">
<td width="552" height="22">
<font face="Arial" size="2" color="#0000FF">Ann Saunders, Ph.D., Therapy
Area Team Leader, Metabolic & Viral Diseases</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">
GlaxoSmithKline</font>
|
<td width="49">
<td width="552">
|
<td width="49"><font size="2" face="Arial" color="#0000FF">10:30</font>
<td width="552"><font size="2" face="Arial" color="#0000FF">Refreshment
Break and Exhibiting</font>
|
<td width="49">
<td width="552">
|
<td width="49" bgcolor="#C0C0C0"><font size="2" face="Arial" color="#0000FF">11:00</font>
<td width="552" bgcolor="#C0C0C0">
<font face="Arial" size="2" color="#0000FF">KEYNOTE SPEAKER</font>
|
<td width="49" bgcolor="#C0C0C0">
<td width="552" bgcolor="#C0C0C0">
<font face="Arial" size="2" color="#0000FF">Steve M. Paul, Executive
Vice President, Lilly Research Labs</font>
|
<td width="49" bgcolor="#C0C0C0">
<td width="552" bgcolor="#C0C0C0">
<font face="Arial" size="2" color="#0000FF">Eli Lilly & Co.</font>
|
<td width="49">
<td width="552">
|
<td width="49"><font size="2" face="Arial" color="#0000FF">12:00</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">Lunch</font>
|
<td width="49">
<td width="552">
|
<td width="49" height="17"><font size="2" face="Arial" color="#0000FF">1:00</font>
<td width="552" height="17">
<font face="Arial" size="2" color="#0000FF">Parkinson's Disease:
Mechanisms and Models</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">Serge
Przedborski, M.D., Ph.D., Professor, Center for Neurology and Behavior</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">Columbia
University College of Physicians and Surgeons</font>
|
<td width="49">
<td width="552">
|
<td width="49"><font size="2" face="Arial" color="#0000FF">1:30</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">The
Therapeutic Potential of Metabotropic Glutamate Receptor Ligands in the
Treatment of Neurodegenerative Disease</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">Michael
Marino, Ph.D., Neuroscience Drug Discovery, Movement Disorders</font>
|
<td width="49">
<td width="552"><font size="2" face="Arial" color="#0000FF">Merck
Research Labs</font>
|
<td width="49">
<td width="552">
|
<td width="49"><font size="2" face="Arial" color="#0000FF">2:00</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">The Role
of Iron and Glutathione in Parkinson's Disease: Toward Rational
Therapeutics</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">Julie
Andersen, Ph.D., Professor</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">Bucks
Institute for Age Research</font>
|
<td width="49">
<td width="552">
|
<td width="49"><font face="Arial" size="2" color="#0000FF">2:30</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">
Neuroprotection and Neurorepair: Small Molecule Approaches for
Parkinson's Disease</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">Michael
J. O'Neill, Principal Research Scientist/Team and Project Leader,
Neurodegeneration Group,</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">Eli Lilly
(UK)</font>
|
<td width="49">
<td width="552">
|
<td width="49"><font size="2" face="Arial" color="#0000FF">3:00</font>
<td width="552"><font size="2" face="Arial" color="#0000FF">Refreshment
Break and Exhibiting</font>
|
<td width="49">
<td width="552">
|
<td width="49"><font size="2" face="Arial" color="#0000FF">3:30</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">
Therapeutic Strategies for the Disease Modification of Alzheimer's
Disease</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">J. Steven
Jacobsen, Ph.D., Associate Director, Neuroscience</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">Wyeth
Research</font>
|
<td width="49">
<td width="552">
|
<td width="49"><font size="2" face="Arial" color="#0000FF">4:00</font>
<td width="552"><font size="2" face="Arial" color="#0000FF">TBA</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">Mark A.
Findeis, Ph.D., Vice President of Research</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">Satori
Pharmaceuticals, Inc.</font>
|
<td width="49">
<td width="552">
|
<td width="49"><font size="2" face="Arial" color="#0000FF">4:30</font>
<td width="552"><font size="2" face="Arial" color="#0000FF">TBA</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">David A.
Lowe, Chief Scientific Officer</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">Memory
Pharmaceuticals Corporation</font>
|
<td width="49">
<td width="552">
|
<td width="49"><font face="Arial" size="2" color="#0000FF">5:30</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">
Networking Reception</font>
|
<td width="629" height="68" colspan="2">
|
<td width="629" colspan="2">
<span style="font-family: Arial; background: silver"><font size="3">DAY
2 - Tuesday, October 11, 2005</font></span>
|
<td width="49">
<td width="552">
|
<td width="49"><font face="Arial" size="2" color="#0000FF">7:15</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">Registration
and Breakfast </font>
|
<td width="49">
<td width="552">
|
<td width="49" align="left" valign="top">
<font size="2" face="Arial" color="#0000FF">8:15</font>
<td width="552"><font size="2" face="Arial" color="#0000FF">Recap of Day
2</font>
|
<td width="49" align="left" valign="top">
<td width="552">
|
<td width="49" align="left" valign="top">
<font face="Arial" size="2" color="#0000FF">8:30</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">Signal
Transduction</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font face="Arial" size="2" color="#0000FF">Zewei
Huang, Ph.D., Professor</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font size="2" face="Arial" color="#0000FF">The
Burnham Institute</font>
|
<td width="49" align="left" valign="top">
<td width="552">
|
<td width="49" align="left" valign="top">
<font size="2" face="Arial" color="#0000FF">9:00</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">A
Delicate Balance: Neuronal Life and Death</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font face="Arial" size="2" color="#0000FF">Carol
Troy, M.D., Ph.D, Associate Professor of Clinical Pathology and
Neurology</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font face="Arial" size="2" color="#0000FF">Taub
Center for the Study of Alzheimer's Disease and the Aging Brain</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font face="Arial" size="2" color="#0000FF">Columbia
University College of Physicians and Surgeons</font>
|
<td width="49" align="left" valign="top">
<td width="552">
|
<td width="49" align="left" valign="top">
<font face="Arial" size="2" color="#0000FF">9:30</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">
Regulatory Pathways that Control Repair and Regeneration</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font face="Arial" size="2" color="#0000FF">Lee
Rubin, Ph.D., Executive Vice President of Research and Chief Scientific
Officer</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font face="Arial" size="2" color="#0000FF">Curis,
Inc.</font>
|
<td width="49" align="left" valign="top">
<td width="552">
|
<td width="49" align="left" valign="top">
<font size="2" face="Arial" color="#0000FF">10:00</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">The
Transcription Factors Activated by Oxidative Stress that May Mediate
Protective or Deleterious Responses</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font face="Arial" size="2" color="#0000FF">Rajiv
Ratan, M.D., Ph.D, Neurology</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font face="Arial" size="2" color="#0000FF">Beth
Israel Deaconess Medical Center, Harvard Medical School</font>
|
<td width="49" align="left" valign="top">
<td width="552">
|
<td width="49" align="left" valign="top">
<font size="2" face="Arial" color="#0000FF">10:30</font>
<td width="552"><font size="2" face="Arial" color="#0000FF">Refreshment
Break and Exhibiting</font>
|
<td width="49" align="left" valign="top">
<td width="552">
|
<td width="49" align="left" valign="top" bgcolor="#C0C0C0">
<font size="2" face="Arial" color="#0000FF">11:00</font>
<td width="552" bgcolor="#C0C0C0">
<font face="Arial" size="2" color="#0000FF">KEYNOTE SPEAKER</font>
|
<td width="49" align="left" valign="top" bgcolor="#C0C0C0">
<td width="552" bgcolor="#C0C0C0">
<font face="Arial" size="2" color="#0000FF">Kevin A. Roth, M.D., Ph.D.,
Director, Neuropathology</font>
|
<td width="49" align="left" valign="top" bgcolor="#C0C0C0">
<td width="552" bgcolor="#C0C0C0">
<font face="Arial" size="2" color="#0000FF">University of Alabama at
Birmingham</font>
|
<td width="49" align="left" valign="top">
<td width="552">
|
<td width="49" align="left" valign="top">
<font size="2" face="Arial" color="#0000FF">12:00</font>
<td width="552"><font size="2" face="Arial" color="#0000FF">Lunch</font>
|
<td width="49" align="left" valign="top">
<td width="552">
|
<td width="49" align="left" valign="top">
<font size="2" face="Arial" color="#0000FF">1:00</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">
Neurodegeneration Approved Drug Screening and Therapeutics Development</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font face="Arial" size="2" color="#0000FF">Jill
Heemskerk, Ph.D., Program Director, Technology Development </font>
|
<td width="49" align="left" valign="top">
<td width="552"><font face="Arial" size="2" color="#0000FF">National
Institute of Neurological Disorders and Stroke, NIH</font>
|
<td width="49" align="left" valign="top">
<td width="552">
|
<td width="49" align="left" valign="top">
<font face="Arial" size="2" color="#0000FF">1:30</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">
Neuroprotection by 3' Substituted Indolones</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font face="Arial" size="2" color="#0000FF">Santosh
R. D'Mello, Ph.D., Professor, Dept of Molecular & Cell Biology</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font face="Arial" size="2" color="#0000FF">
University of Texas at Dallas</font>
|
<td width="49" align="left" valign="top">
<td width="552">
|
<td width="49" align="left" valign="top">
<font size="2" face="Arial" color="#0000FF">2:00</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">
Therapeutic Potential fo Supressing CPK's</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font size="2" color="#0000FF">
<span style="font-family: Arial; font-style: italic">David Park, M.D.</span></font>
|
<td width="49" align="left" valign="top">
<td width="552"><font size="2" color="#0000FF">
<span style="font-family: Arial; font-style: italic">University of
Ottowa</span></font>
|
<td width="49" align="left" valign="top">
<td width="552">
|
<td width="49" align="left" valign="top">
<font face="Arial" size="2" color="#0000FF">2:30</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">Potential
Use of Mood Stabilizing Drugs for Neurodegenerative Diseases</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">De-Maw
Chuang, Ph.D., Chief, Section on Molecular Neurobiology</font>
|
<td width="49">
<td width="552"><font face="Arial" size="2" color="#0000FF">National
Institute of Mental Health, National Institutes of Health</font>
|
<td width="49" align="left" valign="top">
<td width="552">
|
<td width="49" align="left" valign="top">
<font face="Arial" size="2" color="#0000FF">3:00</font>
<td width="552"><font size="2" face="Arial" color="#0000FF">Refreshment
Break and Exhibiting</font>
|
<td width="49" align="left" valign="top">
<td width="552">
|
<td width="49" align="left" valign="top">
<font face="Arial" size="2" color="#0000FF">3:30</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">TBA</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font face="Arial" size="2" color="#0000FF">James
Wang</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font face="Arial" size="2" color="#0000FF">En Vivo</font>
|
<td width="49" align="left" valign="top">
<td width="552">
|
<td width="49" align="left" valign="top">
<font face="Arial" size="2" color="#0000FF">4:00</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">TBA</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font size="2" color="#0000FF">
<span style="font-family: Arial; font-style: italic">Barbara Slusher,
Ph.D., Senior Vice President, Research</span></font>
|
<td width="49" align="left" valign="top">
<td width="552"><font size="2" color="#0000FF">
<span style="font-family: Arial; font-style: italic">Guilford
Pharmaceuticals</span></font>
|
<td width="49">
<td width="552">
|
<td width="49" align="left" valign="top">
<font face="Arial" size="2" color="#0000FF">4:30</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">Oral
Presentations of Selected Abstracts</font>
|
<td width="49" align="left" valign="top">
<td width="552"><font size="2" color="#0000FF">
<span style="font-family: Arial; font-style: italic">To Be Announced on
the GTCbio Website </span></font>
|
<td width="49">
<td width="552">
|
<td width="49"><font face="Arial" size="2" color="#0000FF">5:00</font>
<td width="552"><font face="Arial" size="2" color="#0000FF">
Conference Concludes</font>
|
|
*****On October 11th there will be concurrent sessions on the business and licensing aspects of emerging therapeutics.
|
